0RJT Stock Overview Operates in online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteRedcare Pharmacy NV Competitors Price History & Performance
Summary of share price highs, lows and changes for Redcare Pharmacy Historical stock prices Current Share Price €135.38 52 Week High €171.20 52 Week Low €95.75 Beta 0.97 1 Month Change -5.74% 3 Month Change 12.26% 1 Year Change 5.35% 3 Year Change 20.66% 5 Year Change 209.43% Change since IPO 370.08%
Recent News & Updates
Forecast breakeven date pushed back to 2026 Dec 13
Third quarter 2024 earnings released Nov 10
Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024 Oct 04
Second quarter 2024 earnings released Jul 31
Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG. Jul 30
New minor risk - Share price stability May 29 See more updates
Forecast breakeven date pushed back to 2026 Dec 13
Third quarter 2024 earnings released Nov 10
Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024 Oct 04
Second quarter 2024 earnings released Jul 31
Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG. Jul 30
New minor risk - Share price stability May 29
First quarter 2024 earnings released Apr 26
Now 21% undervalued Apr 05
Redcare Pharmacy NV Announces Management Departures Mar 07
New minor risk - Shareholder dilution Mar 07
Forecast breakeven date moved forward to 2024 Mar 07 Redcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024
Full year 2023 earnings released: €0.73 loss per share (vs €4.32 loss in FY 2022) Mar 06
Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024 Mar 05
Forecast breakeven date moved forward to 2024 Nov 10
Third quarter 2023 earnings released Oct 31
CFO & Member of Management Board recently sold €1.0m worth of stock Aug 11
Second quarter 2023 earnings released: €0.24 loss per share (vs €1.37 loss in 2Q 2022) Aug 02
New minor risk - Profitability Jun 21
Co-Founder recently sold €454k worth of stock May 12
Forecast to breakeven in 2025 May 05
First quarter 2023 earnings released May 03
Forecast to breakeven in 2025 Apr 11
COO & Member of the Managing Board recently sold €331k worth of stock Apr 05
Full year 2022 earnings released: €4.32 loss per share (vs €4.15 loss in FY 2021) Mar 09
No longer forecast to breakeven Mar 08
COO & Member of the Managing Board recently sold €149k worth of stock Jan 31
Forecast to breakeven in 2025 Dec 31
Chairman of the Managing Board & CEO recently bought €85k worth of stock Dec 22 Shop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023
Third quarter 2022 earnings released Nov 03
Co-Founder recently sold €972k worth of stock Aug 28
No longer forecast to breakeven Aug 06
Second quarter 2022 earnings released Aug 05
Shop Apotheke Europe N.V. Re-Confirms Earnings Guidance for 2022 Jul 05
COO & Member of the Managing Board recently sold €1.5m worth of stock Jun 19
Co-Founder recently sold €953k worth of stock Jun 10
No longer forecast to breakeven May 09
First quarter 2022 earnings released May 08
No longer forecast to breakeven Apr 22
Shop Apotheke Europe N.V. (XTRA:SAE) acquired FIRST A. Apr 13
No longer forecast to breakeven Apr 09
Co-Founder recently sold €916k worth of stock Mar 10
Forecast breakeven date pushed back to 2024 Mar 05
Full year 2021 earnings: Revenues in line with analyst expectations Mar 04
Third quarter 2021 earnings released Nov 03
Forecast breakeven pushed back to 2023 Aug 10
Second quarter 2021 earnings released Aug 08
Shop Apotheke Europe Provides Sales Guidance for the Full Year 2021 Aug 06
Shop Apotheke Europe N.V. Revises Earnings Guidance for the Fiscal Year 2021 Jul 24
Shop Apotheke Europe N.V. Announces Earnings Guidance for the Full Year of 2021 Jul 07
Forecast breakeven pushed back to 2022 Jun 16
First quarter 2021 earnings released May 08
Shop Apotheke Europe N.V. Provides Earnings Guidance for the Full Year 2021 May 07
Chairman of the Supervisory Board Jan Pyttel has left the company Apr 30
Chairman of the Managing Board & CEO recently bought €96k worth of stock Mar 14
Full year 2020 earnings released: €1.17 loss per share (vs €2.78 loss in FY 2019) Mar 05
Revenue beats expectations Mar 05
Shop Apotheke Europe N.V. to Report Q2, 2021 Results on Aug 05, 2021 Mar 01
New 90-day high: €203 Feb 03
New 90-day high: €165 Jan 13
Shop Apotheke Europe N.V. to Report Fiscal Year 2020 Results on Mar 03, 2021 Jan 11
Shop Apotheke Europe N.V. (XTRA:SAE) acquired smartpatient gmbh. Jan 09
Shop Apotheke Europe N.V., Annual General Meeting, Apr 21, 2021 Jan 07
Revenue beats expectations Nov 20
Revenue beats expectations Nov 09
New 90-day high: €164 Nov 07
New 90-day high: €162 Oct 05
Shop Apotheke Europe N.V. has completed a Follow-on Equity Offering in the amount of €64.96 million. Oct 01
New 90-day high - €149 Aug 18 Shareholder Returns 0RJT GB Consumer Retailing GB Market 7D -11.1% -2.4% -2.6% 1Y 5.3% 9.0% 2.4%
See full shareholder returns
Return vs Market: 0RJT exceeded the UK Market which returned 2.4% over the past year.
Price Volatility Is 0RJT's price volatile compared to industry and market? 0RJT volatility 0RJT Average Weekly Movement 5.7% Consumer Retailing Industry Average Movement 3.4% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0RJT has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0RJT's weekly volatility (6%) has been stable over the past year.
About the Company Redcare Pharmacy NV operates in online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It provides prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023.
Show more Redcare Pharmacy NV Fundamentals Summary How do Redcare Pharmacy's earnings and revenue compare to its market cap? 0RJT fundamental statistics Market cap €2.77b Earnings (TTM ) -€24.56m Revenue (TTM ) €2.23b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0RJT income statement (TTM ) Revenue €2.23b Cost of Revenue €1.71b Gross Profit €516.65m Other Expenses €541.21m Earnings -€24.56m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.21 Gross Margin 23.20% Net Profit Margin -1.10% Debt/Equity Ratio 45.6%
How did 0RJT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 10:28 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Redcare Pharmacy NV is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Volker Bosse Baader Helvea Equity Research Gerhard Schwarz Baader Helvea Equity Research Alvira Rao Barclays
Show 23 more analysts